CEO Stephen F. Mahoney buys 21,400 shares at $23.33, accumulating first position as stock rallies +55.0% in 30 days amid severe revenue decline.
Stephen F. Mahoney, President and CEO of Viridian Therapeutics, purchased 21,400 shares at $23.33 on 2024-09-27, establishing an initial position. The transaction occurred as the stock was trading near its 52-week high of $23.82 (currently at $22.75, down -4.5% from the peak) and following a sharp 30-day rally of +55.0%. This open-market purchase by the company's top executive represents his first accumulated shareholding but warrants scrutiny given the company's financial deterioration: annual revenue contracted -82.3% and the company posted a net income of $-65.0M on quarterly revenues of just $72.0K. The timing of a CEO's initial equity acquisition while the stock rebounds strongly and the business experiences severe operational headwinds merits close monitoring of subsequent disclosures.